CLART® CMA

CLART® CMA is an *in vitro* diagnostics test line of products for the detection of mutations in genes associated with response to therapy in cancer patients.

**FEATURES OF CMA DIAGNOSTIC KITS**:

- All kits have been validated for automatic and manual DNA extraction from FFPE samples and cell lines.
- Mutational status can be detected for single or multiple genes just combining references.
- High sensitivity and specificity.
- Avoids unnecessary toxicity caused by improper selected antitumor therapy, as well as its associated costs.
- Each mutation is detected in triplicate avoiding unspecific bindings.
- Three internal quality controls included per sample:
  - **Genomic DNA control**: validates the extraction performance.
  - **Amplification control**: avoids false negative results.
  - **Biotin markers**: check the proper performance of the visualization reagents provided with the kit.
- Short turnaround time (5 hours).
- Reduces the amount of sample required. All mutations from any kit can be detected in a single array.
- Compatible with any GENOMICA automation system.

**DATA MANAGEMENT**:

- Automatic reading and interpretation of results (CAR®).
- User-friendly report format (html, bmp).
- Printable, exportable and storable files.

**REPORTING RESULTS**:

Report and image obtained by CAR® reader.
Specific detection of somatic mutations in oncogenes determining response to therapy in colorectal cancer patients.

**MAIN FEATURES:**

**KRAS · BRAF · PI3K:**
- Diagnostic specificity close to 100% in all point mutations.
- Diagnostic sensitivity from 87% to 100% in BRAF and PI3K

**NRAS · iKRAS:**
- Detects the presence of the most prevalent mutations of NRAS and infrequent KRAS with a diagnostic sensitivity and specificity ≥98%.

**ORDERING REFERENCES:**

**KRAS · BRAF · PI3K:**
- CLART® CMA KRAS
  - Amplification 24 tests: CS-0412-24
- CLART® CMA BRAF
  - Amplification 24 tests: CS-0512-24
- CLART® CMA PI3K
  - Amplification 24 tests: CS-0612-24
- CLART® CMA KBP Array
  - Genotyping 24 tests: CS-0712-24

**NRAS · iKRAS:**
- CLART® CMA NRAS · iKRAS
  - Amplification 24 tests: CS-0114-24
- CLART® CMA NiK Array
  - Genotyping 24 tests: CS-0214-24

* Panels can be run and purchased separately.

**BIBLIOGRAPHY:**

Specific detection of somatic mutations, deletions and insertions in EGFR determining response to therapy in non-small-cell lung cancer patients.

EXON 18
- G719A
- G719C
- G719S

EXON 19
- Deletions *

EXON 20
- S768I
- T790M
- 2319 _ 2320 insCAC
- D770 _ N771 insG
- V769 _ D770 insASV
- D770 _ N771 insSVD

EXON 21
- L858R
- L861Q

*6223, 12370, 12370, 6255, 12384, 12382, 6225, 12678, 6218, 12728, 6220, 12419, 6210, 13566, 12386, 12385, 18427, 12403, 12383, 6254, 13561, 12367, 12422, 12387, 26038, 13552, 12416, 23571. (According to COSMIC ID nomenclature).

MAIN FEATURES:
- An average diagnostic sensitivity ≥92% in the most of the mutations.
- Diagnostic specificity ≥99%.

ORDERING REFERENCES:

CLART® CMA EGFR Amplification
24 tests: CS-1014-24

CLART® CMA EGFR Genotyping
24 tests: CS-1114-24

BIBLIOGRAPHY:


2. PAO, W., MILLER, V.A., POLITI, K.A., RIELY, G.J., SOMMAAR, R.


CLART® CMA BRAF · MEK1 · AKT1

Detection of specific somatic mutations in oncogenes determining response to therapy in melanoma patients.

MAIN FEATURES:
- Diagnostic sensitivity in BRAF > 93%.
- The obtained diagnostic specificity for all the mutations in the MEK1 and AKT1 genes is 100%.
- Diagnostic specificity ≥99%.

ORDERING REFERENCES:
BRAF · MEK1 · AKT1:

CLART® CMA BRAF
Amplification 24 tests: CS-0216-24
Genotyping 24 tests: CS-0716-24

CLART® CMA BRAF · MEK1 · AKT1
Amplification 24 tests: CS-0316-24
Genotyping 24 tests: CS-0716-24

BIBLIOGRAPHY:
3. Detection of BRAF V600 mutations in melanoma: evaluation of concordance between the Cobas® 4800 BRAF V600 mutation test and the methods used in French National Cancer Institute (INCa) platforms in a real-life setting.